PDCD1 and neoplasm: Given the robust peripheral immune activation but lack of sustained tumor effector T cells seen with TNFR agonist and checkpoint blockade, we hypothesize that GITR agonist and PD-1 blockade antibody therapy can be benefited by the additional administration of peritumoral DRibbles-pulsed-APCs that can modulate the local TME towards an immune-stimulating environment.